Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis

Parasitology International

Volumn 64, Issue 1, 2015, Pages 70-78

  Thakur, Ankita ^a   Kaur, Harpreet ^a   Kaur, Sukhbir ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Adjuvants; Autoclaved Leishmania donovani antigen; Vaccine; Visceral leishmaniasis

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INACTIVATED VACCINE; INTERLEUKIN 12; LEISHMANIA DONOVANI ANTIGEN; LEISHMANIA VACCINE; LIPOSOME; PARASITE ANTIGEN; PHOSPHORYL LIPID A; SAPONIN; UNCLASSIFIED DRUG; ALUMINUM SULFATE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; LEISHMANIN; LIPID A; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PARASITE LOAD; PROMASTIGOTE; VISCERAL LEISHMANIASIS; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BLOOD; IMMUNOLOGY; LEISHMANIASIS, VISCERAL; PARASITOLOGY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYTOKINES; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNITY, HUMORAL; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LIPID A; LIPOSOMES; MICE; MICE, INBRED BALB C; PARASITE LOAD; SAPONINS; VACCINATION; VACCINES, INACTIVATED;

EID: 84908592591     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2014.10.003     Document Type: Article

References (73)

1. World Health Organization Leishmaniasis 2014, Fact Sheet No. 375, World Health Organization, Geneva.
2. Stockdale L., Newton R. A review of preventative methods against human leishmaniasis infection. PLoS Negl Trop Dis 2013, 7(6):e2278. 10.1371/journal.pntd.0002278.
3. Monzote L. Current treatment of leishmaniasis: a review. Open Antimicrob Agents J 2009, 1:9-19.
4. Rattue G. Visceral Leishmaniasis Vaccine Trial Commences. Medical News Today 2012. Available at: http://www.medicalnewstoday.com/articles/242247.php. (Accessed 23 September 2013).
5. Ravindran R., Ali N. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. Curr Mol Med 2004, 4:697-09.
6. Noazin S., Modabber F., Khamesipour A., Smith P.G., Moulton L.H., Nasseri K., et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 2008, 26:6759-6767.
7. Misra A., Dube A., Srivastava B., Sharma P., Srivastava J.K., Katiyar J.C., et al. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001, 19:3485-3492.
8. + T cell responses and protection against Leishmania major infection. J Exp Med 2002, 195:1565-1573.
9. Srivastava J.K., Misra A., Sharma P., Srivastava B., Naik S., Dube A. Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis. Parasitology 2003, 127:107-114.
10. Michel M.Y., Fathy F.M., Hegazy E.H., Hussein E.D., Eissa M.M., Said D.E. The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis. J Egypt Soc Parasitol 2006, 36:159-176.
11. Nagill R., Mahajan R., Sharma M., Kaur S. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol 2009, 58:359-366.
12. Kamil A.A., Khalil E.A.G., Musa A.M., Modabber F., Mukhtar M.M., Ibrahim M.E., et al. Alum precipitated autoclaved L. major plus BCG, a candidate vaccine for visceral leishmaniasis: safety, skin delayed hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003, 97:365-368.
13. Khalil E.A., Musa A.M., Modabber F., El-Hassan A.M. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major+BCG) in children: an extended phase II study. Ann Trop Paediatr 2006, 26:357-361.
14. Ghalib H., Modabber F. Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. Kinetoplastid Biol Dis 2007, 6:7-20.
15. Musa A.M., Khalil E.A., Mahgoub F.A., Elgawi S.H., Modabber F., Elkadaru A.E., et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008, 102:58-3.
16. Keshavarz Valian H., Khoshabe Abdollah Kenedy L., Nateghi Rostami M., Miramin Mohammadi A., Khamesipour A. Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis. Parasitol Res 2008, 103:21-28. 10.1007/s00436-008-0921-8.
17. Kool M., Fierens K., Lambrecht B.N. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012, 61:927-934.
18. Raman V.S., Duthie M.S., Fox C.B., Matlashewski G., Reed S.G. Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol 2012, 10.3389/fimmu.2012.00144.
19. Marichal T., Ohata K., Bedoret D., Mesnil C., Sabatel C., Kobiyama K., et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011, 17:996-02.
20. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999, 163:4481-4488.
21. Soudi S., Hosseini A.Z., Hashemi S.M. Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice. Parasite Immunol 2011, 33:561-571.
22. Barr I.G., Sjolander A., Cox J.C. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998, 32:247-271.
23. Santos W.R., de Souza E., Palatnik M., Palatnik de Sousa C.B. Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model. Vaccine 1999, 17:2554-2561.
24. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A.B., et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine. Vaccine 2007, 25:6176-6190.
25. Gustafson G.L., Rhodes M.J. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol 1992, 143:483-488.
26. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant: past experiences and new directions. Pharm Biotechnol 1995, 6:495-24.
27. Bojang K., Olodude F., Pinder M., Ofori-Anyinam O., Vigneron L., Fitzpatrick S., et al. Phase I safety and immunogenicity of RTS, S/AS02A candidate malaria vaccine in Gambian children. Vaccine 2005, 23:4148-4157.
28. Reed S., Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect 2005, 7:922-931.
29. Coler R.N., Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005, 21:244-249.
30. Cluff C.W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2010, 667:111-123. 10.1007/978-1-4419-1603-7-10.
31. Watson D.S., Endsley A.N., Huang L. Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012, 30:2256-2272.
32. Nagill R., Kaur S. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine 2010, 28:4002-4012.
33. Ravindran R., Bhowmik S., Das A., Ali N. Comparison of BCG MPL and cationic liposome adjuvant systems in leishmanial antigen formulations against murine visceral leishmaniasis. BMC Microbiol 2010, 10:181. 10.1186/1471-2180-10-181.
34. Shargh V.H., Jaafari M.R., Khamesipour A., Jaafari I., Jalali S.A., Abbasi A., et al. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis. Parasitol Res 2012, 111:105-114. 10.1007/s00436-011-2806-5.
35. Afrin F., Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun 1997, 65:2371-2377.
36. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193:265-275.
37. Sachdeva H., Sehgal R., Kaur S. Asparagus racemosus ameliorates cisplatin induced toxicities and augments its antileishmanial activity by immunomodulation in vivo. Parasitol Int 2014, 63:21-30. 10.1016/j.parint.2013.09.016.
38. Bradley D.J., Kirkley J. Regulation of Leishmania population within the host. I. the variable course of Leishmania donovani infections in mice. Clin Exp Immunol 1997, 30:119-129.
39. + Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 2008, 103:1413-1419.
40. Ravindran R., Anam K., Bairagi B.C., Saha B., Pramanik N., Guha S.K., et al. Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect Immun 2004, 72:863-870.
41. Das A., Ali N. Vaccine development against Leishmania donovani. Front Immunol 2012, 3:99. 10.3389/fimmu.2012.00099.
42. Okwor I., Liu D., Beverley S.M., Uzonna J.E. Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc Natl Acad Sci U S A 2009, 106:13951-13956. 10.1073/pnas.0905184106.
43. Bovier P.A. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 2008, 7:1141-1150.
44. Descamps D.K., Hardt B., Spiessens P., Izurieta T., Verstraeten T., Breuer G., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:332-340.
45. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9:287-293.
46. Sun H.X., Xe Y., Ye Y.P. Advances in saponin-based adjuvants. Vaccine 2002, 27:1787-1796.
47. Lima H.C., Bleyenberg J., Titus R.G. A simple method for quantifying Leishmania in tissues of infected animals. Parasitol Today 1997, 13:80-82.
48. McElrath M.J., Murray H.W., Cohn Z.A. The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med 1988, 167:1927-1937.
49. Badiee A., Jaafari M.R., Khamesipour A., Samiei A., Soroush D., Kheiri M.T., et al. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloid Surf B Interface 2009, 74:37-4. 10.1016/j.colsurfb.2009.06.025.
50. + T cells. Infect Immun 2007, 75:4648-4654.
51. Grenfell R.F.Q., Marques-da-Silva E.A., Souza-Testasicca M.C., Coelho E.A.F., Fernandes A.P., Afonso L.C.C., et al. Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production. Mem Inst Oswaldo Cruz 2010, 105:818-822.
52. Satti I.N., Osman H.Y., Daifalla N.S., Younis S.A., Khalil E.A., Zijlstra E.E., et al. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 2001, 19:2100-2106.
53. Mazumder S., Maji M., Ali N. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy:high immunogenicity and protection. PLoS Negl Trop Dis 2011, 5(12):e1429. 10.1371/journal.pntd.0001429.
54. Santos W.R., de Lima V.M., de Souza E.P., Bernardo R.R., Palatnik M., Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 2002, 22:30-33.
55. Liu Y., Han S., Zhu Y., Li Y., Zhu X., Wang G. Adjuvant effect of saponins isolated from the sepal of Physalis alkekengi L. var. francheti (Mast.) Makino fruit on the immune responses to ovalbumin in mice. J Med Plants Res 2011, 5:3169-3175.
56. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944-947.
57. Mohammadi M.R., Zeinali M., Ardestani S.K., Kariminia A. Identification of novel Leishmania major antigens that elicit IgG2a response in resistant and susceptible mice. Korean J Parasitol 2006, 44:43-48.
58. Marshall D.J., Rudnick K.A., McCarthy S.G., Mateo L.R., Harris M.C., McCauley C., et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine 2006, 24:244-253.
59. Morefield G.L., Hawkins L.D., Ishizaka S.T., Kissner T.L., Ulrich R.G. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin Vaccine Immunol 2007, 14:1499-04.
60. + T lymphocyte responses elicited by a viral vaccine vector. J Virol 2010, 84:10413-10419. 10.1128/JVI.00928-10.
61. Dey R., Dagur P.K., Selvapandiyan A., McCoy J.P., Salotra P., Duncan R., et al. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit longterm protective immunity in BALB/c mice. J Immunol 2013, 190:2138-2149. 10.4049/jimmunol.1202801.
62. Carvalho E.M., Bacellar O., Barral A., Badaro R., Johnson W.D. Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest 1989, 83:860-864.
63. Ghalib H.W., Piuvezam M.R., Skeiky Y.A., Siddig M., Hashim F.A., El-Hassan A.M., et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Investig 1993, 92:324-329.
64. Murphy M.L., Wille U., Villegas E.N., Hunter C.A., Farrell J.P. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001, 31:2848-2856.
65. Mutiso J.M., Macharia J.C., Kariuki T.M., Montanide Gicheru M.M., ISA 720 is more effective than BCG as an adjuvant for Leishmania killed vaccine in BALB/c mice. IJIB 2009, 7:107-116.
66. Bacellar O., D'Oliveira AJr, Jeronimo S., Carvalho E.M. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 2000, 12:1228-1231.
67. Santos W.R., de Souza E., Palatnik M., Palatnik de Sousa C.B. Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model. Vaccine 1999, 17:2554-2561.
68. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A.B., et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine. Vaccine 2007, 25:6176-6190.
69. Rao M., Alving C.R. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv Drug Deliv Rev 2000, 41:171-188.
70. Bhowmick S., Mazumdar T., Ali N. Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect Immun 2009, 77:1514-1523. 10.1128/IAI.01739-07.
71. Khan A.A., Mudassir J., Mohtar N., Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine 2013, 8:2733-2744. 10.2147/IJN.S41521.
72. Peters N.C., Kimblin N., Secundino N., Kamhawi S., Lawyer P., Sacks D.L. Vector transmission of Leishmania abrogates vaccine-induced protective immunity. PLoS Pathog 2009, 5(6):e1000484. 10.1371/journal.ppat.1000484.
73. Oliveira F., Traore B., Gomes R., Faye O., Gilmore D.C., Keita S., et al. Delayed-type hypersensitivity to sandfly saliva in humans from a leishmaniasis-endemic area of MaliisTh1-mediated and persists to midlife. J Invest Dermatol 2013, 133:452-459. 10.1038/jid.2012.315.